Squarepoint Ops LLC Decreases Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Squarepoint Ops LLC lowered its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 69.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 10,102 shares of the biotechnology company's stock after selling 22,752 shares during the quarter. Squarepoint Ops LLC's holdings in Arcturus Therapeutics were worth $171,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Empire Life Investments Inc. grew its position in Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock valued at $4,742,000 after acquiring an additional 128,771 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Arcturus Therapeutics by 5.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 207,802 shares of the biotechnology company's stock valued at $3,526,000 after acquiring an additional 10,180 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in Arcturus Therapeutics by 42.7% in the 4th quarter. Tocqueville Asset Management L.P. now owns 22,400 shares of the biotechnology company's stock valued at $380,000 after acquiring an additional 6,700 shares during the last quarter. American Century Companies Inc. grew its position in Arcturus Therapeutics by 10.7% in the 4th quarter. American Century Companies Inc. now owns 47,018 shares of the biotechnology company's stock valued at $798,000 after acquiring an additional 4,547 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Arcturus Therapeutics in the 4th quarter valued at $71,000. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Stock Down 3.6%

Shares of NASDAQ ARCT traded down $0.46 during mid-day trading on Wednesday, reaching $12.44. 344,978 shares of the company were exchanged, compared to its average volume of 440,038. The stock has a market cap of $337.39 million, a price-to-earnings ratio of -5.60 and a beta of 2.30. Arcturus Therapeutics Holdings Inc. has a 1 year low of $8.04 and a 1 year high of $34.17. The firm has a 50-day moving average of $11.62 and a 200 day moving average of $14.52.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. The firm had revenue of $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. On average, equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on ARCT shares. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Citigroup reissued a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Finally, Scotiabank initiated coverage on Arcturus Therapeutics in a research report on Wednesday, May 28th. They set a "sector outperform" rating and a $32.00 price target on the stock. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Arcturus Therapeutics presently has an average rating of "Buy" and a consensus target price of $53.50.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.